Korean Drugmaker Warned for CGMP Violations

Drug Industry Daily
A A
The FDA hit Korean OTC drugmaker Soleo with a warning letter after finding significant CGMP violations during an Aug. 6-9, 2018 inspection of its Pyeongtaek-Si, Gyeonggi-do facility.

To View This Article:

Login

Subscribe To Drug Industry Daily